培美替尼使胆管癌患者有了新的治疗先择

Recently, the European Commission has approved pemetinib for the treatment of cholangiocarcinoma. As early as April 2020, pemetinib has been approved by the US FDA for the treatment of patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement. Pemetinib was also approved by Japan's MHLW in March 2021. It is the first and only targeted inhibitor approved for the treatment of cholangiocarcinoma in the European Union, the United States, and Japan. This EU approval is an important milestone. It is the first time in more than a decade that the EU has proposed a new treatment option for patients with cholangiocarcinoma with FGFR2 fusion or rearrangement.

Pemetinib, a new drug for intrahepatic cholangiocarcinoma, is an oral inhibitor targeting FGFR1/2/3. Research has found that FGFR2 gene fusion and rearrangement will promote the occurrence and development of intrahepatic cholangiocarcinoma tumors. The new drug pemetinib for intrahepatic cholangiocarcinoma works on the FGFR2 target in patients with intrahepatic cholangiocarcinoma. Pemetinib blocks the signal of abnormal proteins that send reproduction signals to cancer cells. Pemetinib can prevent the growth and spread of cancer cells.

Pemetinib has not been approved for sale in China, and it has not yet been included in the national medical insurance to provide everyone with preferential policies. This means that patients will not be able to buy pemetinib at all in the country. Faced with this situation, more patients choose to go to distant overseas countries to purchase medicines under huge financial pressure. However, this method costs a lot of manpower, material resources and financial resources, which is miserable. However, according to Medical Companion Travel, the pemetinib version is very cost-effective and has been well received by many patients. The specification is 13.5mgx14 tablets and the price is about 341,175$. However, because the price of the drug rises and falls with the fluctuation of the exchange rate in the market, the specific price of the drug is not stable. For more information about pemetinib, please contact Medical Travel for details.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.